All In Biotech

Drug Trial Radar · NCT05057013

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

A Cancer Research UK Phase I/IIa Open Label, Dose Escalation and Expansion Trial of HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours

Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Nov 10, 2021

Primary completion

Nov 2025

Study completion Nov 2025

Sponsor

Lead sponsor
Cancer Research UKAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hummingbird Bioscience
First posted
Sep 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours. The main aims are to find out the best dose of HMBD-001 that can be given to participants alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how they can be treated, and what happens to HMBD-001 inside the body and how it affects cancer cells.

Conditions

  • Bladder Cancer
  • Triple Negative Breast Cancer
  • Castration-resistant Prostate Cancer
  • Cervical Cancer
  • RAS Wild Type Colorectal Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Hepatocellular Carcinoma (HCC)
  • Melanoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Oesophageal Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Squamous Cell Cancer of the Head and Neck

Interventions

  • HMBD-001Drug

    Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.

  • HMBD-001 and enzalutamideDrug

    Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Dose Limiting Toxicities (DLTs); Part ATime frame: From first dose onwards until completion of Cycle 1 (28 days)
  2. Number of Participants Who Experienced DLTs; Part B Arm 1Time frame: From first dose of combination therapy onwards until completion of Cycle 1 (28 days)
  3. Number of adverse events (AEs) by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1)Time frame: From the date of written informed consent until the end of the safety follow-up period (maximum [max] 42 weeks per participant)
  4. Number of Grade 3, 4 and 5 AEs by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1)Time frame: From the date of written informed consent until the end of the safety follow-up period (max 42 weeks per participant)
  5. Overall response rate (ORR) within 6 cycles of HMBD-001 (Part B Arm 1)Time frame: From baseline radiological disease assessment until 28 days after last dose of HMBD-001 (max 36 weeks per participant)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Marsden NHS Foundation Trust

    London, United Kingdom

  • The Christie Hospital

    Manchester, United Kingdom

  • Freeman Hospital, Newcastle

    Newcastle, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.